In an unexpected move, Merck (MRK) scrapped plans to market a biosimilar version of the widely used Lantus insulin only a year after winning tentative U.S. regularly approval. The decision was disclosed in a regulatory filing by Samsung Bioepis, its development and commercialization partner, which noted Merck “suddenly” canceled their contract and returned $155 million.

Merck subsequently explained in a statement that the about-face was prompted after assessing the “anticipated pricing and cost of production.” Although Merck was also locked in patent litigation with Sanofi (SNY), which sells Lantus and had prevented a timely product launch, the move underscores the increasingly crowded insulin market confronting drug makers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy